{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:41:11Z","timestamp":1783698071249,"version":"3.55.0"},"reference-count":123,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hepatitis B virus reactivation (HBVr) poses a serious clinical challenge and potentially life-threatening complication in patients with hepatocellular carcinoma (HCC), particularly amid the expanding use of modern immunotherapeutic agents. Despite progress in antiviral prophylaxis and refined risk-stratification strategies, HBVr continues to compromise treatment efficacy and survival outcomes, especially in patients receiving immune checkpoint inhibitors, tyrosine kinase inhibitors, or combination regimens. This review comprehensively synthesizes current evidence on the virological foundations, clinical risk factors, and immunopathological mechanisms underpinning HBVr during HCC treatment, emphasizing the pivotal roles of covalently closed circular DNA (cccDNA) persistence and treatment-induced immune dysregulation. We further examine the comprehensive evidence of risk factors in HBVr, including various treatments for HCC. We also reviewed the clinical consequences of HBVr, including acute hepatocellular injury, unplanned treatment discontinuations, and adverse long-term HCC prognosis. Evidence-based management approaches, such as universal serological screening, individualized antiviral prophylaxis, and multidisciplinary coordination, are detailed to effectively reduce reactivation risk. Finally, we discuss emerging therapeutic strategies, including HBV-specific cellular therapies and innovative siRNA-based and immunostimulatory cytokine delivery platforms, which offer promising avenues for eradicating viral reservoirs and restoring immune surveillance.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1765054","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T06:46:58Z","timestamp":1770706018000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["HBV reactivation during immunotherapy for hepatocellular carcinoma: risk factors and clinical management"],"prefix":"10.3389","volume":"17","author":[{"given":"Yurou","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Mengchao Hepatobiliary Hospital of Fujian Medical University","place":["Fuzhou, China"]},{"name":"Department of Hepatology and Infectious Diseases, Mengchao Hepatobiliary Hospital of Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Jin","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghui","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Mengchao Hepatobiliary Hospital of Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Fuzhou Second General Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangmin","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mengchao Hepatobiliary Hospital of Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Mengchao Hepatobiliary Hospital of Fujian Medical University","place":["Fuzhou, China"]},{"name":"Department of Hepatology and Infectious Diseases, Mengchao Hepatobiliary Hospital of Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.7989","article-title":"Management of hepatocellular carcinoma: A review","volume":"158","author":"Brown","year":"2023","journal-title":"JAMA Surg"},{"key":"B3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.21037\/hbsn-2024-754","article-title":"2024 latest report on hepatitis B virus epidemiology in China: current status, changing trajectory, and challenges","volume":"14","author":"Yan","year":"2025","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.46234\/ccdcw2025.167","article-title":"World hepatitis day 2025: progress and challenges in the global elimination of viral hepatitis","volume":"7","author":"Li","year":"2025","journal-title":"China CDC Wkly"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.60","article-title":"Novel insights into HBV-hepatocellular carcinoma at single-cell sequencing","volume":"2","author":"Yin","year":"2023","journal-title":"MedComm \u2013 Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/v14050986","article-title":"Hepatitis B virus-associated hepatocellular carcinoma","volume":"14","author":"Rizzo","year":"2022","journal-title":"Viruses"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.08.035","article-title":"Hepatitis B virus-induced hepatocellular carcinoma","volume":"345","author":"Xu","year":"2014","journal-title":"Cancer Lett"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1213145","article-title":"The role of hepatitis B virus genome variations in HBV-related HCC: effects on host signaling pathways","volume":"14","author":"Shoraka","year":"2023","journal-title":"Front Microbiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0342","article-title":"Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection","volume":"29","author":"Lin","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02048","article-title":"HBV-induced immune imbalance in the development of HCC","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"m2200","DOI":"10.1136\/bmj.m2200","article-title":"Hepatitis B virus persistence and reactivation","volume":"370","author":"Shi","year":"2020","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.770124","article-title":"Hepatitis B virus reactivation associated with therapeutic interventions","volume":"8","author":"Chang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.02.042","article-title":"Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies","volume":"28","author":"Mustafayev","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2020.04.002","article-title":"Hepatitis B virus reactivation: what is the issue, and how should it be managed","volume":"24","author":"Ekpanyapong","year":"2020","journal-title":"Clin Liver Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.180389","article-title":"Reactivation of hepatitis B virus associated with immunosuppression therapy","volume":"190","author":"Lee","year":"2018","journal-title":"CMAJ"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.07.003","article-title":"Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion","volume":"77","author":"Papatheodoridis","year":"2022","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i24.7675","article-title":"Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy","volume":"20","author":"Jang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32241","article-title":"Risk of HBV reactivation during therapies for HCC: A systematic review","volume":"75","author":"Papatheodoridi","year":"2022","journal-title":"Hepatology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/v9060156","article-title":"The role of cccDNA in HBV maintenance","volume":"9","author":"Allweiss","year":"2017","journal-title":"Viruses"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/biom15010062","article-title":"HBV cccDNA: the molecular reservoir of hepatitis B persistence and challenges to achieve viral eradication","volume":"15","author":"Boonstra","year":"2025","journal-title":"Biomolecules"},{"key":"B24","doi-asserted-by":"publisher","first-page":"104824","DOI":"10.1016\/j.antiviral.2020.104824","article-title":"Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential","volume":"180","author":"Xia","year":"2020","journal-title":"Antiviral Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/v12030285","article-title":"The interactions between HBV and the innate immunity of hepatocytes","volume":"12","author":"Megahed","year":"2020","journal-title":"Viruses"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2931402","DOI":"10.1155\/2018\/2931402","article-title":"Recent advances in HBV reactivation research","volume":"2018","author":"Guo","year":"2018","journal-title":"BioMed Res Int"},{"key":"B28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","article-title":"Update of the statements on biology and clinical impact of occult hepatitis B virus infection","volume":"71","author":"Raimondo","year":"2019","journal-title":"J Hepatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40249-023-01128-6","article-title":"Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Xia","year":"2023","journal-title":"Infect Dis Poverty"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.7150\/jca.77247","article-title":"Hepatitis B virus reactivation in cancer patients undergoing immune checkpoint inhibitors therapy: A systematic review","volume":"13","author":"Zhao","year":"2022","journal-title":"J Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"112689","DOI":"10.1016\/j.isci.2025.112689","article-title":"HBV reactivation and its management in HBV-related HCC patients undergoing HAIC-TKI-ICI therapy: A multicenter study","volume":"28","author":"Liu","year":"2025","journal-title":"iScience"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2020.08.041","article-title":"Hepatitis B reactivation and immune check point inhibitors","volume":"53","author":"Godbert","year":"2021","journal-title":"Dig Liver Dis"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1002\/hep.32333","article-title":"HCC and HBV reactivation-A preventable condition not to be missed","volume":"75","author":"Sandmann","year":"2022","journal-title":"Hepatology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.trsl.2015.07.010","article-title":"Therapeutics targeting inflammation in the immune reconstitution inflammatory syndrome","volume":"167","author":"Shahani","year":"2016","journal-title":"Transl Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13121675","article-title":"The role of interleukins in HBV infection: A narrative review","volume":"13","author":"Dimitriadis","year":"2023","journal-title":"J Pers Med"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1111\/liv.13631","article-title":"Hepatitis B: Who and when to treat","volume":"38","author":"Vlachogiannakos","year":"2018","journal-title":"Liver Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-019-00236-3","article-title":"Updates on chronic HBV: current challenges and future goals","volume":"17","author":"Lee","year":"2019","journal-title":"Curr Treat Options Gastroenterol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12091146","article-title":"Host and HBV interactions and their potential impact on clinical outcomes","volume":"12","author":"Jose-Abrego","year":"2023","journal-title":"Pathogens"},{"key":"B41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2021.00243","article-title":"Hepatotoxicity induced by biological agents: clinical features and current controversies","volume":"10","author":"Hernandez","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001141","article-title":"Post-transplant hepatitis B virus reactivation impacts the prognosis of patients with hepatitis B-related hepatocellular carcinoma: a dual-centre retrospective cohort study in China","volume":"110","author":"Li","year":"2024","journal-title":"Int J Surg"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/v14071504","article-title":"Occult hepatitis B virus infection: an update","volume":"14","author":"Saitta","year":"2022","journal-title":"Viruses"},{"key":"B45","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"B46","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i24.3052","article-title":"Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors","volume":"30","author":"Savaliya","year":"2024","journal-title":"World J Gastroenterol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i26.3193","article-title":"Reactivation of hepatitis B virus infection - an important aspect of multifaceted problem","volume":"30","author":"Morozov","year":"2024","journal-title":"World J Gastroenterol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i12.1531","article-title":"Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy","volume":"17","author":"Manzano-Alonso","year":"2011","journal-title":"World J Gastroenterol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2016.1177017","article-title":"Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders","volume":"16","author":"Vigano","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae105","article-title":"Hepatitis B virus reactivation risk associated with immune checkpoint inhibitors in tumor treatment: a retrospective study","volume":"54","author":"Yin","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.05.014","article-title":"Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma","volume":"41","author":"Jang","year":"2004","journal-title":"J Hepatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12356","article-title":"Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load","volume":"22","author":"Sohn","year":"2015","journal-title":"J Viral Hepat"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2013.03.020","article-title":"Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study","volume":"39","author":"Dan","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-018-4006-4","article-title":"Identification of actual 10-year survival after hepatectomy of HBV-related hepatocellular carcinoma: a multicenter study","volume":"23","author":"Li","year":"2019","journal-title":"J Gastrointest Surg"},{"key":"B56","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/SLA.0b013e318262b218","article-title":"Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels","volume":"257","author":"Huang","year":"2013","journal-title":"Ann Surg"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1840","article-title":"Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma","volume":"16","author":"Jang","year":"2011","journal-title":"Antivir Ther"},{"key":"B58","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12957-023-02921-1","article-title":"Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma","volume":"21","author":"Liu","year":"2023","journal-title":"World J Surg Oncol"},{"key":"B59","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.surge.2010.07.011","article-title":"Surgery induced immunosuppression","volume":"9","author":"Hogan","year":"2011","journal-title":"Surgeon"},{"key":"B60","doi-asserted-by":"crossref","DOI":"10.1093\/carcin\/bgae012","article-title":"Surgical stress induced tumor immune suppressive environment","volume":"45","author":"Yang","year":"2024","journal-title":"Carcinogenesis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"8864655","DOI":"10.1155\/2021\/8864655","article-title":"Hepatitis B virus reactivation potential risk factors in hepatocellular carcinoma via transcatheter arterial chemoembolization: A retrospective research","volume":"2021","author":"Wang","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00232.x","article-title":"Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study","volume":"100","author":"Park","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz860","article-title":"Association of prophylactic anti-hepatitis B virus therapy with improved long-term survival in patients with hepatocellular carcinoma undergoing transarterial therapy","volume":"71","author":"Jang","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.13121498","article-title":"Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization","volume":"267","author":"Yu","year":"2013","journal-title":"Radiology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/liv.12112","article-title":"Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma","volume":"33","author":"Lao","year":"2013","journal-title":"Liver Int"},{"key":"B66","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13027-024-00574-7","article-title":"Hepatitis B virus reactivation in hepatocellular carcinoma patients after hepatic arterial infusion chemotherapy combined with and without immunotherapy","volume":"19","author":"Zhang","year":"2024","journal-title":"Infect Agent Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201316","article-title":"Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study","volume":"13","author":"Jun","year":"2018","journal-title":"PloS One"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.04.005","article-title":"Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma","volume":"69","author":"Kim","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-022-10450-4","article-title":"Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors","volume":"17","author":"Lei","year":"2023","journal-title":"Hepatol Int"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-008-0496-x","article-title":"Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area","volume":"135","author":"Shim","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.12.004","article-title":"The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelines","volume":"82","author":"Wong","year":"2025","journal-title":"J Hepatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"30204","DOI":"10.1038\/s41598-025-13406-4","article-title":"HBV reactivation and prognosis after systemic therapy in HCC with undetectable HBV DNA: a multicenter retrospective study","volume":"15","author":"Liang","year":"2025","journal-title":"Sci Rep"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.12.021","article-title":"Emerging vaccine nanotechnology: From defense against infection to sniping cancer","volume":"12","author":"Feng","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"B74","first-page":"1825","article-title":"Personalized cancer vaccine approach safe in early trial","volume":"325","author":"Abbasi","year":"2021","journal-title":"JAMA"},{"key":"B75","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.cgh.2021.06.019","article-title":"Risk of hepatitis B virus reactivation in patients treated with immunotherapy for anti-cancer treatment","volume":"20","author":"Yoo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c10818","article-title":"Chiral nanosilica drug delivery systems stereoselectively interacted with the intestinal mucosa to improve the oral adsorption of insoluble drugs","volume":"17","author":"Chen","year":"2023","journal-title":"ACS Nano"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad100","article-title":"The immunopathogenesis of immune reconstitution inflammatory syndrome has become clearer, but more complex","volume":"228","author":"French","year":"2023","journal-title":"J Infect Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.11.042","article-title":"Hybrid core-shell particles for mRNA systemic delivery","volume":"353","author":"Andretto","year":"2023","journal-title":"J Control Release"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202210452","article-title":"Biomaterial-based in situ cancer vaccines","volume":"36","author":"Bo","year":"2024","journal-title":"Adv Mater"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-02978-7","article-title":"Prompt initiation of durvalumab and tremelimumab for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B: a phase 2 clinical trial","volume":"132","author":"Shao","year":"2025","journal-title":"Br J Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhep.2023.09.011","article-title":"PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B","volume":"80","author":"Chun","year":"2024","journal-title":"J Hepatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2023.02.026","article-title":"ROS Scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease","volume":"161","author":"Bao","year":"2023","journal-title":"Acta Biomater"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14475","article-title":"The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy","volume":"40","author":"Loglio","year":"2020","journal-title":"Liver Int"},{"key":"B84","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12951-021-01146-2","article-title":"Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy","volume":"19","author":"Cai","year":"2021","journal-title":"J Nanobiotechnology"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2024.09.024","article-title":"A polymer nanogel-based therapeutic nanovaccine for prophylaxis and direct treatment of tumors via a full-cycle immunomodulation","volume":"43","author":"Guo","year":"2025","journal-title":"Bioact Mater"},{"key":"B86","article-title":"Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/INMD.20240134","article-title":"Racing toward the future of chronic hepatitis B management: Achieving functional cure and enhancing hepatocellular carcinoma surveillance through precision medicine","volume":"3","author":"Shi","year":"2025","journal-title":"Interdiscip Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/v17030388","article-title":"HBV reactivation in immunosuppressed patients: screening, prevention, and management including solid organ transplant recipients","volume":"17","author":"Vutien","year":"2025","journal-title":"Viruses"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01146","article-title":"Second primary cancer risks after breast cancer in BRCA1 and BRCA2 pathogenic variant carriers","volume":"43","author":"Allen","year":"2025","journal-title":"J Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2174\/1567201820666230518161330","article-title":"Oral insulin delivery: A review on recent advancements and novel strategies","volume":"21","author":"Barfar","year":"2024","journal-title":"Curr Drug Deliv"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc2816","article-title":"Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines","volume":"13","author":"Chen","year":"2021","journal-title":"Sci Transl Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"3814809","DOI":"10.1155\/2022\/3814809","article-title":"HIF-1alpha regulates the progression of cervical cancer by targeting YAP\/TAZ","volume":"2022","author":"Abudoukerimu","year":"2022","journal-title":"J Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2013.02.099","article-title":"Hepatitis B \u201c360","volume":"45","author":"Schilsky","year":"2013","journal-title":"Transplant Proc"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09988-7","article-title":"APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation","volume":"13","author":"Kanda","year":"2019","journal-title":"Hepatol Int"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1785","article-title":"Selective EGLN inhibition enables ablative radiotherapy and improves survival in unresectable pancreatic cancer","volume":"79","author":"Fujimoto","year":"2019","journal-title":"Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200101000-00020","article-title":"Reactivation of viral replication after liver resection in patients infected with hepatitis B virus","volume":"233","author":"Kubo","year":"2001","journal-title":"Ann Surg"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-007-0121-3","article-title":"A study into the risk of exacerbation of chronic hepatitis B after liver resection for hepatocellular carcinoma","volume":"11","author":"Thia","year":"2007","journal-title":"J Gastrointest Surg"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12472","article-title":"Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus","volume":"29","author":"Lee","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2011.06888.x","article-title":"Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma","volume":"27","author":"Huang","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12036","article-title":"Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial","volume":"20","author":"Huang","year":"2013","journal-title":"J Viral Hepat"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijsu.2014.12.030","article-title":"Perioperative antiviral therapy improves safety in patients with hepatitis B related HCC following hepatectomy","volume":"15","author":"Zhang","year":"2015","journal-title":"Int J Surg"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24044","article-title":"Postoperative hepatitis B virus reactivation and surgery-induced immunosuppression in patients with hepatitis B-related hepatocellular carcinoma","volume":"112","author":"Xie","year":"2015","journal-title":"J Surg Oncol"},{"key":"B103","article-title":"Postoperative hepatitis B virus reactivation in hepatitis B virus-related hepatocellular carcinoma patients with hepatitis B virus DNA levels <500 copies\/mL","volume":"9","author":"Xie","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14789","article-title":"Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma","volume":"8","author":"Gong","year":"2017","journal-title":"Oncotarget"},{"key":"B105","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jamcollsurg.2016.11.009","article-title":"Antiviral therapy inhibits viral reactivation and improves survival after repeat hepatectomy for hepatitis B virus-related recurrent hepatocellular carcinoma","volume":"224","author":"Huang","year":"2017","journal-title":"J Am Coll Surg"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2018.11.007","article-title":"High CONUT score predicts poor survival and postoperative HBV reactivation in HBV-related hepatocellular carcinoma patients with low HBV-DNA levels","volume":"45","author":"Wang","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"B107","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjsurg.2019.05.016","article-title":"Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm - A retrospective cohort study","volume":"219","author":"Wang","year":"2020","journal-title":"Am J Surg"},{"key":"B108","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S1386-6346(03)00158-X","article-title":"Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC","volume":"26","author":"Nagamatsu","year":"2003","journal-title":"Hepatol Res"},{"key":"B109","doi-asserted-by":"crossref","DOI":"10.1002\/hep.21024","article-title":"A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization","volume":"43","author":"Jang","year":"2006","journal-title":"Hepatology"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2011.00796.x","article-title":"Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma","volume":"41","author":"Lao","year":"2011","journal-title":"Hepatol Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S91618","article-title":"The hepatitis B virus reactivation after transarterial chemoembolization in Chinese hepatocellular carcinoma patients with low serum hepatitis B virus DNA level","volume":"11","author":"Shao","year":"2015","journal-title":"Ther Clin Risk Manage"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.582504","article-title":"Effects of antiviral therapy on HBV reactivation and survival in hepatocellular carcinoma patients undergoing hepatic artery infusion chemotherapy","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1533033819875136","DOI":"10.1177\/1533033819875136","article-title":"Analysis of hepatitis B virus reactivation after radiotherapy in patients with hepatocellular carcinoma using the lyman NTCP model","volume":"18","author":"Li","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"B114","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/cas.12400","article-title":"Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma","volume":"105","author":"Huang","year":"2014","journal-title":"Cancer Sci"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12805","article-title":"A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib","volume":"35","author":"Yang","year":"2015","journal-title":"Liver Int"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12898","article-title":"Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib","volume":"30","author":"Lim","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000525499","article-title":"Hepatic events and viral kinetics in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab","volume":"12","author":"Hsu","year":"2023","journal-title":"Liver Cancer"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001072","article-title":"Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"8","author":"Lee","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02911-w","article-title":"Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis","volume":"70","author":"He","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B120","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s00432-024-05677-7","article-title":"Risk of HBV reactivation in HCC patients undergoing combination therapy of PD-1 inhibitors and angiogenesis inhibitors in the antiviral era","volume":"150","author":"Wang","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","article-title":"Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition","volume":"7","author":"Zhang","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B122","doi-asserted-by":"publisher","first-page":"10732748241309046","DOI":"10.1177\/10732748241309046","article-title":"Hepatitis B virus reactivation in patients with HBV-related advanced hepatocellular carcinoma undergoing lenvatinib and camrelizumab treatment","volume":"32","author":"Sheng","year":"2025","journal-title":"Cancer Control"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.865124","article-title":"Reactivation of occult hepatitis B virus infection during long-term entecavir antiviral therapy","volume":"13","author":"Yuan","year":"2022","journal-title":"Front Microbiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1765054\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T06:47:01Z","timestamp":1770706021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1765054\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":123,"alternative-id":["10.3389\/fimmu.2026.1765054"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1765054","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"article-number":"1765054"}}